0001178913-17-002494.txt : 20170821 0001178913-17-002494.hdr.sgml : 20170821 20170821160337 ACCESSION NUMBER: 0001178913-17-002494 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170821 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20170821 DATE AS OF CHANGE: 20170821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PLURISTEM THERAPEUTICS INC CENTRAL INDEX KEY: 0001158780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980351734 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31392 FILM NUMBER: 171043176 BUSINESS ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 31905 BUSINESS PHONE: 972-74-710-7171 MAIL ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 31905 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC DATE OF NAME CHANGE: 20030701 FORMER COMPANY: FORMER CONFORMED NAME: AI SOFTWARE INC DATE OF NAME CHANGE: 20010906 8-K 1 zk1720469.htm 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 21, 2017 (August 15, 2017)

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
  
98-0351734
(Commission File Number)
  
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
  
31905
(Address of Principal Executive Offices)
  
(Zip Code)

011 972 74 7108607
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company  ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 

Item 1.01.  Entry into Material Definitive Agreement.
 
On August 15, 2017, the registrant extended the deadline to consummate the terms of the previously announced binding term sheet with Sosei Corporate Venture Capital Ltd. for the establishment of a new Japanese corporation for the clinical development and commercialization of the registrant’s PLX-PAD cell therapy product in Japan, until December 31, 2017.
 
Warning Concerning Forward Looking Statements
 
This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements include, but are not limited to those statements regarding the establishment of a new Japanese corporation. Although the registrant has signed a binding term sheet, it may not be successful in negotiating definitive documentation by the date expected or at all, and even if successful, the transaction may not be completed if the conditions to closing are not met. These forward-looking statements and their implications are based on the current expectations of the management of the registrant only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this Current Report on Form 8-K are subject to risks and uncertainties, including those discussed in the registrant’s reports filed from time to time with the SEC. Except as otherwise required by law, the registrant undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
 
 
 
 
 
Date: August 21, 2017
By:
/s/ Erez Egozi
 
 
 
Name:  Erez Egozi
 
 
 
Title:    Chief Financial Officer